CA Patent

CA3118965A1 — Treatment of obesity and its complications

Assigned to CymaBay Therapeutics Inc · Expires 2020-05-22 · 6y expired

What this patent protects

Combination treatment of obesity and its complications with seladelpar or a salt thereof, and a glucagon-like peptide-1 (GLP-1) receptor agonist.

USPTO Abstract

Combination treatment of obesity and its complications with seladelpar or a salt thereof, and a glucagon-like peptide-1 (GLP-1) receptor agonist.

Drugs covered by this patent

Patent Metadata

Patent number
CA3118965A1
Jurisdiction
CA
Classification
—
Expires
2020-05-22
Drug substance claim
No
Drug product claim
No
Assignee
CymaBay Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.